Association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas. Issue 2 (30th September 2022)
- Record Type:
- Journal Article
- Title:
- Association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas. Issue 2 (30th September 2022)
- Main Title:
- Association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas
- Authors:
- Liouta, Evangelia
Kalyvas, Aristotelis V
Komaitis, Spyridon
Drosos, Evangelos
Koutsarnakis, Christos
García-Gómez, Juan M
Juan-Albarracín, Javier
Katsaros, Vasileios
Kalamatianos, Theodosis
Argyrakos, Theodoros
Stranjalis, George - Abstract:
- Abstract: Background: High-grade glioma (HGG) patients present with variable impairment in neurocognitive function (NCF). Based on that, isocitrate dehydrogenase 1 (IDH1) wild-type HGGs are more aggressive than IDH1 mutant-type ones, we hypothesized that patients with IDH1 wild-type HGG would exhibit more severe NCF deficits than their IDH1 mutant counterparts. Methods: NCF was assessed by Mini Mental Status Exam (MMSE), Trail Making Test (TMT), Digit Span (DS), and Controlled Word Association Test (COWAT) tests in 147 HGG patients preoperatively. Results: Analyses between IDH1 groups revealed a significant difference on MMSE concentration component ( p ≤ .01), DS ( p ≤ .01), TMTB ( p ≤ .01), and COWAT ( p ≤ .01) scores, with the IDH1 wild group performing worse than the IDH1 mutant one. Age and tumor volume were inversely correlated with MMSE concentration component ( r = −4.78, p < .01), and with MMSE concentration ( r = −.401, p < .01), TMTB ( r = −.328, p < .01), and COWAT phonemic scores ( r = −.599, p < .01), respectively, but only for the IDH1 wild-type group. Analyses between age-matched subsamples of IDH1 groups revealed no age effect on NCF. Tumor grade showed nonsignificance on NCF ( p > .05) between the 2 IDH1 mutation subgroups of grade IV tumor patients. On the contrary, grade III group showed a significant difference in TMTB ( p < .01) and DS backwards ( p < .01) between IDH1 subgroups, with the mutant one outperforming the IDH1 wild one. Conclusions: OurAbstract: Background: High-grade glioma (HGG) patients present with variable impairment in neurocognitive function (NCF). Based on that, isocitrate dehydrogenase 1 (IDH1) wild-type HGGs are more aggressive than IDH1 mutant-type ones, we hypothesized that patients with IDH1 wild-type HGG would exhibit more severe NCF deficits than their IDH1 mutant counterparts. Methods: NCF was assessed by Mini Mental Status Exam (MMSE), Trail Making Test (TMT), Digit Span (DS), and Controlled Word Association Test (COWAT) tests in 147 HGG patients preoperatively. Results: Analyses between IDH1 groups revealed a significant difference on MMSE concentration component ( p ≤ .01), DS ( p ≤ .01), TMTB ( p ≤ .01), and COWAT ( p ≤ .01) scores, with the IDH1 wild group performing worse than the IDH1 mutant one. Age and tumor volume were inversely correlated with MMSE concentration component ( r = −4.78, p < .01), and with MMSE concentration ( r = −.401, p < .01), TMTB ( r = −.328, p < .01), and COWAT phonemic scores ( r = −.599, p < .01), respectively, but only for the IDH1 wild-type group. Analyses between age-matched subsamples of IDH1 groups revealed no age effect on NCF. Tumor grade showed nonsignificance on NCF ( p > .05) between the 2 IDH1 mutation subgroups of grade IV tumor patients. On the contrary, grade III group showed a significant difference in TMTB ( p < .01) and DS backwards ( p < .01) between IDH1 subgroups, with the mutant one outperforming the IDH1 wild one. Conclusions: Our findings indicate that IDH1 wild-type HGG patients present greater NCF impairment, in executive functions particularly, compared to IDH1 mutant ones, suggesting that tumor growth kinetics may play a more profound role than other tumor and demographic parameters in clinical NCF of HGG patients. … (more)
- Is Part Of:
- Neuro-oncology practice. Volume 10:Issue 2(2023)
- Journal:
- Neuro-oncology practice
- Issue:
- Volume 10:Issue 2(2023)
- Issue Display:
- Volume 10, Issue 2 (2023)
- Year:
- 2023
- Volume:
- 10
- Issue:
- 2
- Issue Sort Value:
- 2023-0010-0002-0000
- Page Start:
- 132
- Page End:
- 139
- Publication Date:
- 2022-09-30
- Subjects:
- cognition -- executive functions -- high-grade gliomas -- IDH1 mutation -- neuropsychological testing
Brain -- Tumors -- Periodicals
Brain -- Cancer -- Periodicals
Nervous system -- Cancer -- Periodicals
616.99481005 - Journal URLs:
- http://nop.oxfordjournals.org/ ↗
http://www.oxfordjournals.org/en/ ↗ - DOI:
- 10.1093/nop/npac077 ↗
- Languages:
- English
- ISSNs:
- 2054-2577
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26801.xml